Woodline Partners LP Janux Therapeutics, Inc. Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,600,263 shares of JANX stock, worth $98.5 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares

1,600,263

Previous 300,825 431.96%

Holding current value

$98.5 Million

Previous $12.6 Million 476.93%

% of portfolio

0.66%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$35.29 - $50.26 $45.9 Million - $65.3 Million	1,299,438 Added 431.96%	1,600,263 $72.7 Million
Q2 2024 Aug 14, 2024	BUY	$35.12 - $64.78 $9.52 Million - $17.6 Million	270,977 Added 907.86%	300,825 $12.6 Million
Q1 2024 May 15, 2024	BUY	$7.93 - $49.75 $236,694 - $1.48 Million	29,848 New	29,848 $1.12 Million
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $493,219 - $722,288	-51,592 Reduced 37.58%	85,708 $863,000
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $4.14 Million - $8.17 Million	-368,064 Reduced 72.83%	137,300 $1.66 Million
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $1.17 Million - $1.92 Million	105,183 Added 26.28%	505,364 $6.66 Million
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $1.23 Million - $1.92 Million	113,798 Added 39.74%	400,181 $5.42 Million
Q2 2022 Aug 15, 2022	BUY	$9.52 - $15.65 $76,731 - $126,139	8,060 Added 2.9%	286,383 $3.5 Million
Q1 2022 May 16, 2022	BUY	$13.24 - $20.24 $635 - $971	48 Added 0.02%	278,323 $3.99 Million
Q4 2021 Feb 14, 2022	SELL	$15.44 - $27.32 $335,912 - $594,373	-21,756 Reduced 7.25%	278,275 $5.49 Million
Q3 2021 Nov 15, 2021	SELL	$20.7 - $34.69 $708,540 - $1.19 Million	-34,229 Reduced 10.24%	300,031 $6.49 Million
Q2 2021 Aug 16, 2021	BUY	$18.58 - $25.37 $6.21 Million - $8.48 Million	334,260 New	334,260 $8.34 Million

Others Institutions Holding JANX

# of Institutions

166

Shares Held

37.6M

Call Options Held

85.3K

Put Options Held

654K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.56B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Janux Therapeutics, Inc. Transaction History